Is enxidipine included in domestic medical insurance?

Enasidenib is an oral, targeted inhibitor used to treat a specific type of acute myeloid leukemia (AML). It is a treatment option for patients with AML who have mutations in IDH2 (isocitrate dehydrogenase 2).

Ensidipine has not yet obtained marketing approval in China, so domestic patients cannot directly purchase the drug and must purchase it through overseas channels. In foreign countries, relatively affordable drugs are generic drugs, especially those produced in Laos and Bangladesh, which sell for between 2,000 and 4,000 yuan. It is worth mentioning that there is almost no difference in the pharmaceutical ingredients between these generic drugs and the original drugs.

AML is a type of leukemia caused by the proliferation of abnormal white blood cells in the bone marrow. Ensidipine treats AML by inhibiting the activity of IDH2 mutant enzyme. IDH2The abnormal activity of the mutant enzyme will lead to the production of large amounts of 2-hydroxyvaleric acid (2-HG), thereby interfering with the normal differentiation and proliferation of cells. Ensidipine works by reducing 2-HG levels and restoring normal cell differentiation and proliferation, thereby helping to control the development of AML.

Ensidipine is an oral medication usually recommended at a dose of 100mg once daily. Before starting treatment, doctors typically perform a detailed clinical evaluation and ensure that the patient has IDH2-mutated AML. During treatment, the doctor may adjust the dosage based on the patient's specific condition and disease progression.

Clinical trials have shown that ensidipine demonstrated significant anti-tumor activity in the treatment of patients with IDH2mutated AML and produced durable clinical responses in some patients. However, like any drug treatment, ensidipine may also cause some adverse reactions, such as nausea, vomiting, fatigue, etc..